Drug development for neglected tropical diseases and orphan diseases is a risky and costly business. While the societal need for treatment is clear, the economic case to pursue and launch such drugs is often tenuous. Tropical diseases severely hamper local development, where purchasing power is already low, and orphan diseases only affect very small percentages of the population. From an investment perspective, for these two types of disease, market pull is not there.

Partnership can bridge this funding gap by sharing costs and mitigating risks. TI Pharma brings organizations together to pursue drug development for neglected and orphan diseases by helping them pool their resources, secure funding, and share the risks involved.

TI Pharma supports several such partnerships, including:

“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”

Hugo Hurts
Director/Secretary of the Medicines Evaluation Board

Hugo Hurts
Director/Secretary of the Medicines Evaluation Board

Share this page: